TMTatiana N. Moiseeva

Tatiana N. Moiseeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tatiana N. Moiseeva has a total of 177 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnosis of Metachronous Classical and Nodular Lymphocyte-Predominant Hodgkin Lymphomas: A Case Report and Pathogenetic Issues

    by Irina Aleksandrovna Shupletsova, A. M. Kovrigina, Yu. V. Sidorova, E. I. Dorokhina, T. N. Moiseeva

    Among В-cell tumors, there are composite/discordant lymphomas characterized by either synchronous or metachronous development, however, a combination of nodular lymphocyte-predominant Hodgkin lymphoma with classical Hodgkin lymphoma is extremely rare. This paper documents a similar case. It provides evidence for ‘plasticity’ of B-cell precursors, which can initiate lymphoid tumor growth at various stages of B-cell differentiation.

  • Open Access

    Multicenter randomized controlled (comparative) open prospective study to evaluate the efficacy of the R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cell transplantation programs in untreated patients with de novo diffuse B-cell large cell lymphoma with signs of poor prognosis (final results)

    by A. U. Magomedova, Ya. K. Mangasarova, S. K. Kravchenko, A. M. Kovrigina, O. V. Margolin, E. A Fastova, F. E. Babaeva, M. J. Bagova, L. G. Gorenkova, E. S. Nesterova, et al.

    Introduction. The R-NHL-BFM-90 protocol has been successfully used for the treatment of Burkitt’s lymphoma and diffuse large B-cell lymphoma (DLBCL) in children and adolescents, as well as adult T-cell lymphomas. The protocol was modified for the treatment of adult patients with de novo nodal DLBCL.Aim: to evaluate the efficacy and toxicity of the R-mNHL-BFM-90 and R-DA-EPOCH-21 protocols in adult patients with de novo nodal DLBCL with 2 or more signs of poor prognosis, as well as to determine the role of auto-HSCT in the consolidation of remission.Materials and methods. From 2015 to 2021, 164 patients were evaluated for randomization. The study included 140 patients from 13 Russian medical centers. 89 (76 %) patients with de novo nodal DLBCL: R-DAEPOCH-21 20 (22.5 %) patients; R-DAEPOCH-21 + auto-HSCT 21 (23.5 %) patients; R-mNHL-BFM-90 20 (22.5 %) patients; R-mNHL-BFM-90 performed + auto-HSCT 28 (31.5 %) patients. In the high-intermediate and high-risk group, there were 12 (29.3 %) and 29 (70.7 %) patients on the R-DA-EPOCH-21 + auto-HSCT protocol and 15 (31.2 %) and 32 (66.7 %) on the R-mNHL-BFM-90 protocol + auto-HSCT, respectively.Results. The R-mNHL-BFM-90 protocol proved to be more effective. Complete remission in the high-risk group was achieved in 30 (93.7 %) patients versus 18 (62.0 %), there was no progression versus 3 (10.3 %) patients treated according to R-DA-EPOCH-21 (p = 0.0167). The five-year overall and event-free survival in the high-risk group was 97 % vs. 75 % (p = 0.01) and 97 % vs. 72 % (p = 0.0026), respectively. In the intermediate risk group, the results of therapy did not differ. The toxicity of the R-mNHL-BFM-90 protocol exceeded the toxicity of R-DA-EPOCH-21 only in neutropenic fever (p = 0.04) and grade 3–4 thrombocytopenia (p = 0.0009).Conclusion. The R-mNHL-BFM-90 protocol is effective for the treatment of patients with nodal de novo DLBCL diffuse large B-cell lymphoma of high-risk adults; its toxicity is acceptable. However, on the R-DA-EPOCH-21 therapy, the results of therapy are unsatisfactory. The R-DA-EPOCH-21 protocol with auto-HSCT was more effective than without auto-HSCT, however, due to the small number of patients, the results were unpresentative. The results of therapy according R-mNHL-BFM-90 protocol with auto-HSCT and without auto-HSCT were not differ.

  • Open Access

    Illness Representations and Treatment Adherence in Patients with Acute Leukemia and Lymphoma

    by L.V. Esina, D.E. Vybornykh, E.I. Rasskazova, E.G. Gemdzhian, E.E. Zvonkov, I.A. Lukyanova, T.N. Moiseeva, A.U. Magomedova

    This study aims to investigate the relationship between of perceptions of illness and its causes, body and health, and illness behavior in relation to treatment adherence in patients with acute leukemia and lymphoma. We present one empirical study involving lymphoma patients (N=58) aged 19 to 64 years (M=41.22; SD=11.17), of whom 70.7% were female, and acute leukemia patients (N=51) aged 18 to 64 years (M=35.12; SD=12.90), of whom 54.9% were female. Participants completed the Illness Perception Questionnaire-Revised (IPQ-R), the Cognitions about body and health questionnaire (CABAH), the Scale for the Assessment of Illness Behavior (SAIB) and 4-item Morisky Medication Adherence Scale. The results suggest that patients with lymphoma are at risk for decreased treatment adherence compared to patients with acute leukemia. In acute leukemia, the targets of psychological work aimed at preventing reduced adherence to treatment are patients' perceptions of the psychological causes of the disease and their belief that healthy habits are not important for maintaining health, while in patients with lymphomas — uncertainty that immune problems could provoke the disease.


  • Open Access

    MEK-kinase Inhibitor as a treatment option for hairy cell leukemia

    by Л. С. Аль-Ради, S. Yu. Smirnova, T. N. Moiseeva, I. A. Yakutik, A. B. Sudarikov, M. A. Guryanova, E. O. Gribanova, E. N. Dvirnyk, A. M. Kovrigina

    Introduction. Hairy cell leukemia (HCL) is a chronic indolent B–cell lymphoproliferative disease with a good response to treatment in most cases. However, despite successful treatment, there remains a group of patients with a resistant/recurrent course of the disease, a short remission after treatment, and with contraindications to standard therapy. The use of the RASRAF- MEK-ERK pathway inhibitor in the V600E marker mutation of the BRAF gene may prove to be an effective treatment option for complicated/resistant cases of HCL.Aim — to present the results of the use MEK-kinase inhibitor trametinib in the treatment of HCL.Main findings. The MEK-kinase inhibitor trametinib was used at a dose of 1 mg/day for 3 months in three patients. In two patients trametinib was used as preliminary stage before the main course of treatment with cladribine. In one patient with a resistant/relapsing course of HCL, trametinib monotherapy made it possible to achieve a good partial remission, and the treatment continues without a decrease in the quality of life.Conclusion. Trametinib can be used as a preliminary stage before analogous purine treatment in patients with HCL without the BRAF V600E mutation, in a case of deep neutropenia or infectious complications, and as the main antitumor therapy in patients with resistant/recurrent HCL. Trametinib is effective in the absence of the MAP2K1 mutations. Trametinib monotherapy can be effective at a reduced dosage (1 mg/day or 1 mg every other day).

  • Open Access

    Adherence to treatment of hematological malignancies patients with anxiety and depression

    by D E Vybornykh, T N Moiseeva, E G Gemdzhian, T V Gaponova, L V Esina, E I Kolgaeva, D V Novikova

    Aim. To establish the features of the influence of anxiety and depressive disorders on treatment adherence, as well as to clarify the factors associated with it in hematologic malignancies patients. Materials and methods. The study included 117 patients: 51 men and 66 women, aged 19 to 67 years, with Hodgkin's lymphoma 88, acute lymphoblastic leukemia 16 and aplastic anemia 13 patients. Patients were examined by psychiatrist using the Brief Psychiatric Rating Scale, as well as some psychometric methods. Results. Anxiety-depressive spectrum disorders were detected in 36 (40.9%) patients with Hodgkin's lymphoma and 8 (50%) with acute lymphoblastic leukemia, in the aplastic anemia group there were three (23.1%) of such patients. It was found that the average adherence to treatment was in 2/3 of patients, low and high in the remaining 1/3 of patients. With medium and low adherence to treatment, the risk of adverse events increases by an average of 1.7 times. The adherence to treatment it is significantly higher in patients older than 45 years. Signs of depression that negatively correlated with adherence to treatment were pessimism and disruption of social ties. Adherence to treatment significantly positively correlates with the following types of attitudes towards the disease: anosognosic, hypochondriac and egocentric, and significantly negatively correlates with the following types of attitudes towards the disease: anxious, melancholic and dysphoric. Conclusion. Anxiety/depressive disorders contribute to reduced adherence of hematologic malignancies patients to treatment. Their correction and increased adherence should be carried out jointly by hematologists and mental health professionals.


  • Open Access

    Experience of using acalabrutinib therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

    by I. S. Piskunova, T. N. Moiseeva, Л. С. Аль-Ради, L. V. Plastinina

    Introduction. Thanks to scientific advances and discoveries in the study of tumor cell biology, new effective drugs for the treatment of chronic lymphocytic leukemia/ small lymphocytic lymphoma have emerged. Currently, there are drugs with different application points at the molecular level. One such drug is acalabrutinib, which is a selective second-generation inhibitors of Bruton tyrosine kinase and has a more favorable toxicity profile.Objective. To evaluate the efficacy of acalabrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.Materials and methods. Since February 2020 acalabrutinib (100 mg 2 p/day orally) has been administered to 7 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (mean age 64 years) at the Hematology Research Center. Six patients received acalabrutinib in 1st-line therapy and one patient received acalabrutinib in 2nd-line therapy. The mean comorbidity index (CIRS) of the patients was 10 points (range, 8 to 14). Most patients had at least one of the adverse prognostic factors - IGHV nonmutated gene status, TP53 gene aberration (del17p13 and/or TP53 gene mutation), complex karyotype disorders.Results. All patients achieved partial remission of the disease (overall response 100% in the form of regression of B-symptoms, lymphocytic leukocytosis, splenomegaly) at the control period of treatment with acalabrutinib +12 months. The most frequent adverse events when taking acalabrutinib were the occurrence of headache in the first month of taking the drug, spontaneous subcutaneous hematomas. No hematologic toxicity, infectious complications, or cardiac complications were noted. At a median follow-up of 34 months, no patient showed disease progression.Conclusions. The selective Bruton tyrosine kinase inhibitor acalabrutinib has demonstrated high efficacy in patients with adverse risk factors, good tolerability and minimal toxicity, including in comorbid patients.

  • Open Access

    Pathomorphological and clinical characteristics of blastic plasmocytoid dendritic cell neoplasm. Case report

    by Andrei A. Sherstnev, Alla M. Kovrigina, Tatiana I. Solovyova, Tatiana N. Moiseeva, Соловьева Татьяна Ивановна

    The paper reveals the 5 cases date about blastic plasmacytoid dendritic cell neoplasm. The presented information demonstrates morphological, immunohistochemical data and clinical manifestations.

  • Open Access

    Fibronectin: structure, functions, clinical significance (review)

    by S. A. Vasiliev, L. A. Gorgidze, E. E. Efremov, G. Yu. Belinin, T. N. Moiseeva, Л. С. Аль-Ради, M. A. Sokolova, G. T. Guria, N. I. Zozulya, A. V. Kokhno

    Plasma fibronectin is a high molecular weight adhesive glycoprotein. There are two types of fibronectin: plasma (soluble) and cellular derived (insoluble). Electron microscopy revealed two types of structural organization of fibronectin: compact and expanded. In solution, fibronectin has a compact conformation, and after binding to certain substrates (collagen, fibrin, heparin), it is expanded. Plasma fibronectin is one of the main opsonins of blood plasma in relation to the “targets” of phagocytosis of a predominantly non-bacterial nature, as well as to some types of bacteria. For the treatment of septic processes, as well as respiratory distress syndrome of adults with severe fibronectin deficiency, plasma cryoprecipitate is used – a donor plasma preparation containing a large amount of plasma fibronectin (more than 2 mg/ml). It was proposed to replenish the level of fibronectin in patients with sepsis and other conditions that cause plasma fibronectin deficiency with the help of donor freshly frozen plasma. Transfusion of large volumes of freshly frozen plasma (up to 1000–1500 ml) to patients effectively eliminates the deficiency of plasma fibronectin. The concentration of plasma fibronectin in the blood significantly decreases after the addition of severe infectious processes to hematological diseases, as well as acute DIC syndrome. Extracorporeal methods of blood purification – selective plasmapheresis – have been developed to correct immunocomplex and fibronectin-complex pathology. Two variants of selective plasmapheresis have been proposed: the method of heparinocryoprecipitation of plasma proteins and the method of heparinocryofractionation. In 1987, a plasma heparin precipitate was proposed as a source of fibronectin for the treatment of patients with trophic skin lesions. In 1992, a new method was proposed for obtaining blood preparations with a high concentration of plasma fibronectin from patients themselves (heparin cryofractionation). Autofibronectin preparations obtained by such methods are effective in the local treatment of trophic ulcers in 90–93% of cases. The proposed drugs are safe against infection of patients with infectious diseases transmitted through the blood.


  • Open Access

    Large B-cell lymphoma with IRF4 rearrangement

    by L. V. Plastinina, T. N. Moiseeva, Л. С. Аль-Ради, A. M. Kovrigina, T. N. Obukhova, S. R. Goryacheva, I. A. Shupletsova, A. U. Magomedova, S. K. Kravchenko

    Introduction. Large B-cell lymphoma with IRF4 rearrangement is rare disease, recently described in WHO 2017, arising in children and young adults, presenting with enlarged lymph nodes of the head and neck and/or Waldeyer ring. It is characterized by strong expression of MUM1 protein with IRF4 rearrangement.Aim — to present a clinical case of large B-cell lymphoma with IRF4 rearrangement and characterize its clinical, morphological, and cytogenetic features.Main findings. An observation of a patient with a rare case of large B-cell lymphoma with IRF4 rearrangement is presented.In-depth morphological, immunohistochemical analysis, and additional research methods made it possible to establish a correct diagnosis. Features of the case were the predominantly diffuse growth of large tumor cells in the lymph node biopsy with the indolent clinical course, and the presence of aberrations in both homologues of chromosome 6: IRF4 rearrangement and deletion 6p25. Treatment with 4 R-CHOP-21 courses allowed for the achievement of disease remission, which continued 26 months post treatment.

  • Open Access

    Adult still’s disease – a multidisciplinary disease

    by Leonid I. Dvoretsky, Daria V. Novikova, Anna V. Torgashna, Alla M. Kovrigina, Tatiana N. Moiseeva, Roza M. Vakolyuk, Maria A. Karnaushkina